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ABSTRACT
We describe a woman with no previous liver disease who developed drug-induced autoimmune hepatitis from hydralazine
prescribed to her for hypertension. Despite the discontinuation of themedication, she developed acute liver failure and subsequently
underwent successful liver transplantation. She survived and had a good clinical outcome.
INTRODUCTION
Drug-induced liver injury (DILI) is a significant cause of morbidity and mortality, accounting for at least 13% of acute liver failure
cases in the United States.1 It is the leading cause of acute liver failure among patients referred for liver transplantation and the most
common reason that drugs in development do not obtain the Food and Drug Administration approval. The incidence of DILI has
been reported to be 1:10,000 to 1:100,000 patients; however, the actual incidence is probably higher in part because of the difficulty in
diagnosis.2 Liver damage can range frombenign elevations in the liver enzymes that resolve after the discontinuation of the offending
agent, all the way to liver failure and even death. This case highlights a rare but important cause of drug-induced autoimmune liver
injury, ultimately leading to acute liver failure and requiring liver transplantation.
CASE REPORT
A 51-year-old woman with a history of hypertension, diabetes, coronary artery disease requiring stent placement, and cerebro-
vascular accident with left-sided residual weakness presented to the hospital for 2 months of generalized fatigue, malaise, poor
appetite, nausea, and worsening altered mental status. In the last 2 weeks, her symptoms had progressively worsened and were
subsequently brought into the hospital by her family.
The patient had no known drug allergies. Three months before admission, the patient was started on hydralazine 10mg per oral (PO),
3 times per day because of difficulty in controlling high blood pressure. She had no other new medications but was also taking the
following at home: amlodipine 10mg POdaily, carvedilol 6.25mg PO2 times per day, lisinopril 5 mg POdaily, and aspirin 325mg PO
daily.Owing to thepatient’s alteredmental status, a thorough social historywas obtained from the family. They reported that the patient
did not engage in any high-risk behaviors that would put her at risk for viral hepatitis, alcoholic hepatitis, or nonprescription DILI.
Vitals signs were within the normal range, and physical examination findings were consistent with scleral icterus, dry mucous
membranes, and no rashes on the skin including the face. Her chest was without spider angiomas, abdomen with no hep-
atosplenomegaly, no shifting dullness, no surgical scar, normoactive bowel sounds, extremities without palmar erythema, and no
pitting edema. The neurological examination noted that the patient opens her eyes to noxious stimuli (sternal rub) but otherwise
does not respond to verbal commands. Asterixis were present; Table 1 lists all pertinent laboratory findings.
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With no previous history of chronic liver disease, international
normalized ratio above 1.5, and worsening altered mental
status, the patient was deemed to be in acute liver failure
meeting King’s College criteria for nonacetaminophen-induced
acute liver failure.3 After extensive negative workup, the
etiology was determined to be secondary to DILI in an
autoimmune fashion, likely because of hydralazine. The re-
mainder of the patient’s medications were reviewed on the
National Institute of Health LiverTox website showing
no association with drug-induced autoimmune hepatitis
(DI-AIH), in particular, carvedilol and lisinopril.4 The
patient required a liver transplantation and explant pathol-
ogy confirmed the diagnosis (Figure 1). A liver biopsy was
not obtained before transplantation because of the patient’s
continued coagulopathy and high risk of bleeding. Further-
more, the patient had no contraindications to liver trans-
plantation. Therefore, a liver biopsy would not have changed
the management. Post-transplant, the patient recovered well
and was discharged home after 10 days of postoperative
hospitalization. The patient presented to the liver transplant
clinic at a follow-up and was back to functional baseline
having normal graft function without evidence of graft re-
jection in the first-year post-transplant.
The gross examination of the 833 g total hepatectomy speci-
men, and the attached gallbladder showed a smooth pink liver
capsule with cut sections, demonstrating a tan-brown homo-
geneous surface with focal hemorrhage. No masses, lesions, or
dominant nodules were identified within the liver parenchyma,
grossly. The hepatic and portal veins were patent without
evidence of thrombi. The gallbladder was unremarkable.
Histologic sections of the liver demonstrated diffuse hepatocyte
necrosis and interface hepatitis, consistent with fulminant au-
toimmune hepatitis.
DISCUSSION
Hydralazine is a commonly used antihypertensive drug which
acts by direct relaxation of arteriolar smoothmuscle, probably by
alteration in intracellular calcium signaling.1 Themechanism for
liver injury is thought to be because of its metabolism to an
immunologic adduct that can result in immunoallergic hepatitis
or delayed lupus-like and/or autoimmune hepatitis-like syn-
drome.1 Hydralazine, similar to isoniazid, is metabolized by
N-acetyltransferase, and hepatic injury may be more frequent
with specific genetic variants in N-acetyltransferase activity.1
Liver injury secondary to hydralazine can range from a mild
immunologic reaction that self-resolves after discontinuation of
the drug to liver failure requiring liver transplantation.
This case highlights the findings in DI-AIH and persistence of
liver failure requiring transplantation despite discontinuation of
the offending agent. We noted antinuclear antibodies and anti-
smooth muscle positivity on serology suggestive of AIH, which
were negative in the past in our patient.Workup, including urine
and blood drug screens, resulted negative. Liver biopsy described
scarce plasma cells and interphase hepatitis further supporting
the diagnosis of AIH. The temporal relationship of hydralazine
use, the absence of a previous history of liver disease, and com-
patible histology are highly suggestive of hydralazine as the cul-
prit cause. Furthermore, the liver biopsy did not show any
evidence of steatosis or steatohepatitis. Our patient met several
Table 1. Laboratory studies
Basic metabolic panel: Viral hepatitis: Autoimmune and metabolic workup:
Na: 132, K: 4.1, Cl: 102, CO2: 24, BUN:
23, Cr: 1.3
Hepatitis A total Ab: detected ANA: 1:320
Liver Chemistries: Hepatitis A IgM: Nondetectable ASMA: 1:40
TB: 18.9, AST: 576, ALT: 374, albumin 4.2,
total protein: 7.8, alkaline phosphatase:
187, gamma-glutamyl transferase (GGT):
278
HBsAg: Nonreactive IgG serum levels: 1,290
CBC: HBcAb: Nonreactive AMA: , 1:20
WBC: 8.7, H/H: 13.7/38, PLT: 75 HCVAb: Nonreactive Anti-LKM: Nondetectable
INR: 3.3 Hepatitis E IgG and IgM: Nondetectable A1AT: Normal
Urine drug screen: All negative HIV: Nonreactive Ceruloplasmin, ferritin, iron, and TIBC:
Within normal limits
CMV, HSV, HBV, HCV, and HIV PCR:
Nondetectable
A1AT, alpha-one antitrypsin; Ab, antibody; ALT, alanine aminotransferase; AMA, anti-mitochondrial antibody; ANA, antinuclear antibodies; Anti-LKM, anti-liver-kidney
microsomal antibody; ASMA, anti-smoothmuscle antibody; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Cl, chloride; CO2, carbon dioxide; Cr, creatinine; H/H,
hemoglobin/hematocrit; HBcAb, hepatitis B core antibody; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HCVabva, hepatitis C antibody;
HIV, human immunodeficiency virus; HSV, herpes simplex virus; IgG, immunoglobulin G; IgM, immunoglobulin M; INR, international normalized ratio; K, potassium; Na,
sodium; PCR, polymerase chain reaction; PLT, platelets; TB, total bilirubin; TIBC, total iron binding capacity; WBC, white blood cell.
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diagnostic criteria for AIH as established in the AASLD guide-
lines for AIH, with previously described compatible liver his-
tology, positive AIH serum biomarkers, immunochemistries,
and autoantibodies, along with negative viral markers and other
potential etiological factors for her fulminant hepatitis. Her
pretreatment aggregate score forAIHwas. 15,which correlated
with a “definitive diagnosis.”5 Physical examination findings
included the absence of spider angiomas, palmar erythema, and
ascites; therefore, there was no suggestion of chronic liver disease
on history and physical examination to indicate previous non-
alcoholic steatohepatitis of episodes or multiple episodes of AIH
flares. A computed tomography scan of the abdomen also did not
show any findings suggestive of sequela of portal hypertension
such as splenomegaly or formation of collaterals. This was a new
insult to the liver causing acute liver failure with very low like-
lihood of acute on chronic liver injury.
Autoimmune hepatitis and DI-AIH can mimic each other sero-
logically, and on liver biopsy, a high clinical suspicion must be
present.6Onpathology, both idiopathicAIHandDI-AIHcaseswill
have interface hepatitis, focal necrosis, and portal inflammation,
but these findings tend to be more severe in idiopathic AIH rather
than DI-AIH. Our patient had some hepatocellular cholestasis
which can help distinguish idiopathic AIH from DI-AIH. How-
ever, we did not see portal neutrophils which tend to be more
prevalent in DI-AIH.7 In our case, the temporal relationship with
hydralazine administration, lack of evidence for chronic liver dis-
ease, andnegativeAIHserologies in thepastwere key indiagnosing
DI-AIH. Our patient was instructed not to receive hydralazine in
the future as the liver damage can recur. Hydralazine has been
implicated in DI-AIH in the past with a similar pattern of DI-AIH
liver injury.8–10 The previously reported case studies suggest that
a lupus-like syndromecanbepresent at times.10Ourpatientdidnot
have any rashes to suggest a lupus-like syndrome.
In conclusion, DI-AIH is a rare but serious event that can often
be difficult to diagnose.1,2,11 A high degree of clinical suspicion is
required for the diagnosis of DI-AIH. This diagnosis should be
suspected in patients who develop liver injury and an immu-
noallergic reaction while taking a drug implicated in this type of
liver injury. Complete recovery of liver injury is most often seen
with DI-AIH; however, cases of prolonged injury may occur,
requiring treatment with immunosuppressive therapy, and
cases such as ours requiring liver transplantation have been
described. This type of liver injury should be documented in the
medical record to avoid rechallenge with the drug in the future.
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Figure 1. Histologic hematoxylin and eosin stained sections of explant pathology at (A) magnification 43, (B) magnification 103, and (C)
magnification 203, showing diffuse panlobular hepatocyte necrosis and focal areas of centrilobular zone III necrosis and small areas of intact
tissue. There was extensive hepatocellular dropout with stromal collapse and replacement by mixed inflammatory cell infiltrates composed
predominantly of lymphocytes and ductular reaction. Minimal hepatocellular cholestasis was seen. The native bile ducts appeared un-
remarkable. (D) Trichrome and (E) reticulin stain showing similar findings with no fibrosis (magnification 103). An iron stain shows (F) focal
hemosiderin deposition within viable hepatocytes (magnification 103).
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